871 results on '"Edelman, Martin J."'
Search Results
102. Clinical and pharmacologic study of tributyrin: an oral butyrate prodrug
103. Cell cycle-dependent potentiation of cisplatin by UCN-01 in non-small-cell lung carcinoma
104. The management of the patient undergoing combined modality therapy for locally advanced non-small cell lung cancer
105. Opportunities and Challenges in the Era of Molecularly Targeted Agents and Radiation Therapy
106. Follow-up of local (stage I and stage II) non-small-cell lung cancer after surgical resection
107. Novel Cytotoxic Agents for Non-small Cell Lung Cancer
108. Interactions of gemcitabine, carboplatin and paclitaxel in molecularly defined non-small-cell lung cancer cell lines
109. Activity of high-dose toremifene plus cisplatin in platinum-treated non-small-cell lung cancer: a phase II California Cancer Consortium Trial
110. Advanced non-small cell lung cancer
111. Promoter Methylation and Response to Chemotherapy and Radiation in Esophageal Cancer
112. Phase II study of PKC-α antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer
113. Geographic Variation in the Second-Line Treatment of Non–Small Cell Lung Cancer
114. Phase I study of docetaxel and topotecan in patients with solid tumors
115. New approaches to treatment of metastatic bladder cancer
116. Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non–Small-Cell Lung Cancer
117. Multicenter Trial of EC145 in Advanced, Folate-Receptor Positive Adenocarcinoma of the Lung
118. The Underappreciated Role of the Humoral Immune System and B Cells in Tumorigenesis and Cancer Therapeutics: A Review
119. Clinical Trials in the Age of Pandemics
120. Targeting Cancer Stem Cells and Metastasis with Epigenetic Modulation and Anti-HER2 Therapy: Phase I/II Trial of Vorinostat in Combination with Lapatinib
121. Biomarker Testing in Lung Cancer—What Does It Mean?
122. A War on Two Fronts: Cancer Care in the Time of COVID-19
123. New Therapies in Special Populations
124. Prophylactic Cranial Irradiation for Small-Cell Lung Cancer: Time for a Reassessment
125. Alternative Multidisciplinary Management Options for Locally Advanced Non-Small Cell Lung Cancer During the COVID-19 Global Pandemic
126. EML4/ALK and Ras Inhibitors
127. High-dose toremifene as a cisplatin modulator in metastatic non-small cell lung cancer: targeted plasma levels are achievable clinically
128. Phase II trial of pyrazine diazohydroxide in androgen-independent prostate cancer
129. Consensus proposal for 5HT3 antagonists in the prevention of acute emesis related to highly emetogenic chemotherapy: Dose, schedule, and route of administration
130. Phase I trial of edatrexate plus carboplatin in advanced solid tumors: amelioration of dose-limiting mucositis by ice chip cryotherapy
131. Lung Cancer in Women: Emerging Differences in Epidemiology, Biology, and Therapy
132. An Update on the Role of Epidermal Growth Factor Receptor Inhibitors in Non–Small Cell Lung Cancer
133. High-dose radiotherapy in trimodality treatment of Pancoast tumors results in high pathologic complete response rates and excellent long-term survival
134. Phase II trial of edatrexate plus carboplatin in metastatic non-small-cell lung cancer: a Southwest Oncology Group study
135. The Utility of Follow-up Testing After Curative Cancer Therapy: A Critical Review and Economic Analysis
136. Pemetrexed-Induced Typhlitis in Non-small Cell Lung Cancer
137. Promising new agents in the treatment of non-small cell lung cancer
138. Erratum to: Phase I and pharmacokinetic evaluation of the anti-telomerase agent KML-001 with cisplatin in advanced solid tumors
139. The Potential Role of Bortezomib in Combination with Chemotherapy and Radiation in Non-Small-Cell Lung Cancer
140. Phase II Trial of the Novel Retinoid, Bexarotene, and Gemcitabine Plus Carboplatin in Advanced Non–Small-Cell Lung Cancer
141. Gemcitabine in Patients with Non–Small-Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy: A Phase II California Cancer Consortium Trial
142. Pulmonary Resection After Curative Intent Radiotherapy (>59 Gy) and Concurrent Chemotherapy in Non–Small-Cell Lung Cancer
143. Phase I Study of G3139, a bcl-2 Antisense Oligonucleotide, Combined With Carboplatin and Etoposide in Patients With Small-Cell Lung Cancer
144. Phase II Trial of Cisplatin/Etoposide and Concurrent Radiotherapy Followed by Paclitaxel/Carboplatin Consolidation for Limited Small-Cell Lung Cancer: Southwest Oncology Group 9713
145. Taking stock of targeted therapy in cancer: rational expectations or irrational exuberance?
146. Platinum-Free combination Chemotherapy in Patients with advanced or Metastatic transitional cell carcinoma
147. Gemcitabine and Carboplatin Regimens in Advanced Non-Small-Cell Lung Cancer: Focus on Randomized Phase III Trials
148. Case-control study of PD-1, PD-L1 and B7-H3 expression in lung cancer patients with and without human immunodeficiency virus (HIV) infection
149. Unfavorable Therapeutic Index of Cisplatin/Gemcitabine/Vinorelbine in Advanced Non-Small-Cell Lung Cancer
150. Neoadjuvant chemotherapy in early-stage non-small cell lung cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.